Science AI Journal
Medicine · Research topic

Open research questions in COVID-19 Clinical Research Studies

281 unresolved questions extracted from the limitations and future-work sections of 1,693 COVID-19 Clinical Research Studies papers in our library. Each links back to the study that raised it.

What the literature leaves open

  • The paper identifies the challenge of addressing the spread of misinformation about prescription stimulants on social media. It highlights the need to develop effective clinician-led communication strategies to prevent non-medical use and diversion of prescription stimulants. The paper also emphasizes the challenge of distinguishing trustworthy from untrustworthy information on social media.

    Methylphenidate as a ‘study drug’: lessons from the COVID-19 infodemic for preventing non-medical use · 2026 · DOI

  • The paper identifies a gap in addressing the non-medical use of prescription stimulants as 'study drugs' through clinician-led communication. There is a need to distinguish self-identification with ADHD traits from clinical evaluation and to clarify that modest cognitive effects do not make non-medical use safe or legitimate.

    Methylphenidate as a ‘study drug’: lessons from the COVID-19 infodemic for preventing non-medical use · 2026 · DOI

  • The study notes that missing data, particularly for CRP and D-dimer, may have introduced bias into the analysis. The study also notes that the use of different laboratory thresholds and sampling times may have affected the results. The study acknowledges that residual confounding may have occurred due to the lack of data on certain variables, such as COVID-19 severity and hepatotoxic medications.

    Association of inflammatory markers with abnormal liver biochemistry in hospitalized patients with COVID-19: a cross-sectional study · 2026 · DOI

  • investigation of the mechanisms underlying the association between ferritin and abnormal liver biochemistry, - examination of the impact of COVID-19 severity on liver biochemistry, - study of the role of other inflammatory markers in COVID-19-related liver injury

    Association of inflammatory markers with abnormal liver biochemistry in hospitalized patients with COVID-19: a cross-sectional study · 2026 · DOI

  • Understanding the dynamics and mechanisms behind cross-species transmissions is crucial to proactively assessing and mitigating the risk of new diseases or pandemics derived from CoVs

    New insights into the pathogenesis of SARS-CoV-2 during and after the COVID-19 pandemic · 2024 · DOI

  • INTRODUCTION: SARS-CoV-2 and influenza viruses can lead to liver involvement, although the extent and clinical significance remain unclear.

    Hepatitis is an underestimated complication among children with pneumonia associated with SARS-CoV-2 and influenza: a single center study · 2026 · DOI

  • The role of CXC ligand 13 (CXCL13), a chemokine produced homeostatically by various lung cell types, in protecting against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and disease remains controversial.

    CXCL13/CXCR5 chemokine axis promotes antiviral CXCR5+CD19+ B Cells and follicular/effector CXCR5+CD4+ T Cells in the lungs associated with protection from severe and fatal COVID-19 following infection with pathogenic SARS-CoV-2 Delta variant · 2026 · DOI

  • Some previous studies suggest a risk of fibrotic consequences of COVID-19 disease but little is known yet.

    HRCT Chest Findings in Moderate to Severe Post Covid-19 Patients at 4 To 8 Weeks Follow Up · 2026 · DOI

  • Although obesity is known to alter immune function, the mechanisms by which it affects local and systemic SARS-CoV-2 immunity and worsens disease severity remain unclear.

    Obesity Alters the Metabolic and Immunologic Response of Pulmonary T Cells to SARS-CoV-2 Infection 2143 · 2025 · DOI

  • Despite the growing recognition of microbiome alterations in COVID-19, the precise mechanisms by which SARS-CoV-2 interacts with the microbiome and influences disease progression remain poorly understood.

    Microbiome dysbiosis in SARS-CoV-2 infection: implication for pathophysiology and management strategies of COVID-19 · 2025 · DOI

  • However, the specific mechanisms by which TLR7 activation shapes SARS-CoV-2-specific immune responses, particularly via IRF-IFN pathways, remain incompletely elucidated.

    Unraveled role of TLR7-mediated interferon signaling activation in COVID-19 · 2025 · DOI

  • The safety and effectiveness of Azvudine in treating COVID-19 patients with KD remain unknown.

    Real-world effectiveness and safety of oral Azvudine versus Paxlovid for COVID-19 in patients with kidney disease: a multicenter, retrospective, cohort study · 2025 · DOI

  • Importance: The profile of gastrointestinal (GI) tract outcomes associated with the postacute and chronic phases of COVID-19 in children and adolescents remains unclear.

    Pediatric Gastrointestinal Tract Outcomes During the Postacute Phase of COVID-19 · 2025 · DOI

  • It explores emerging therapeutic strategies targeting cytokines like IL-6, TNF-α, and IFN-γ, while also addressing open questions, such as the need for better biomarkers to detect and manage cytokine storms.

    Cytokine Storm in COVID-19: Exploring IL-6 Signaling and Cytokine-Microbiome Interactions as Emerging Therapeutic Approaches · 2024 · DOI

  • Introduction The prognostic ability of myocardial injury across different waves of the COVID-19 pandemic is not well established.

    Prevalence and prognostic implications of myocardial injury across different waves of COVID-19 · 2024 · DOI

  • Therapeutic strategies for this virus are still inconclusive and understanding its entry mechanism is important for finding effective treatments.

    Lipid rafts disruption by statins negatively impacts the interaction between SARS-CoV-2 S1 subunit and ACE2 in intestinal epithelial cells · 2024 · DOI

  • However, the underlying cause for the depletion of T-cells in COVID-19 patients remains incompletely understood.

    Decreased progenitor TCF1 + T-cells correlate with COVID-19 disease severity · 2024 · DOI

  • However, the characteristics of immune cells in the gastrointestinal tract of COVID-19 patients and their association with these symptoms remain unclear.

    Spatial immune landscapes of SARS-CoV-2 gastrointestinal infection: macrophages contribute to local tissue inflammation and gastrointestinal symptoms · 2024 · DOI

  • The principal limitations of this study included the lack of longitudinal analysis and limited sample size.

    Evaluation of IFNAR2 and TYK2 transcripts’ prognostic role in COVID-19 patients: a retrospective study · 2024 · DOI

  • BACKGROUND: COVID-19 has been shown to increase the risk of extracorporeal coagulation during hemodialysis in patients, but the underlying mechanism remains unclear.

    COVID-19 increases extracorporeal coagulation during hemodialysis associated with upregulation of vWF/FBLN5 signaling in patients with severe/critical symptoms · 2024 · DOI

  • BACKGROUND: Predictors of the outcome of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection remain to be fully determined.

    T cell-mediated Immune response and correlates of inflammation and their relationship with COVID-19 clinical severity: not an intuitive guess · 2024 · DOI

  • Despite the reduced severity of the omicron variants, many patients become severely ill after infection and undergo invasive mechanical ventilation, but there are few reports on their background and prognosis throughout all variant periods.

    Evaluation of characteristics and prognosis of COVID-19 patients requiring invasive mechanical ventilation during dominance of nonvariant, alpha, delta, and omicron variants in tertiary hospitals of Japan · 2024 · DOI

  • No studies have compared COVID-19 outcomes in patients with chronic kidney disease (CKD) and patients with impaired renal function without a prior diagnosis of CKD.

    Prognostic significance of chronic kidney disease and impaired renal function in Japanese patients with COVID-19 · 2024 · DOI

  • Future research should focus on further elucidating these mechanisms and exploring their potential clinical applications in managing COVID-19 severity.

    Immunopathological markers and cell types linked to COVID-19 symptom manifestation · 2024 · DOI

  • BACKGROUND: The clinical benefit of coronavirus disease 2019 (COVID-19) treatments against new circulating variants remains unclear.

    Characteristics and outcomes of patients with COVID-19 at high risk of disease progression receiving sotrovimab, oral antivirals, or no treatment: a retrospective cohort study · 2024 · DOI

Most-cited papers in COVID-19 Clinical Research Studies

Most recent work

Find a gap in your own COVID-19 Clinical Research Studies sub-topic

This page shows what the COVID-19 Clinical Research Studies literature already flags as unresolved. To narrow it to your specific question, run the guided finder — it searches the gap library on demand and checks candidates against 250M+ OpenAlex works.

Open the Research Gap Finder →

Related topics in Medicine

Artificial Intelligence in Healthcare and Education
2,044 open questions
Substance Abuse Treatment and Outcomes
1,964 open questions
Smoking Behavior and Cessation
990 open questions
Dementia and Cognitive Impairment Research
974 open questions
Innovations in Medical Education
960 open questions
Physical Activity and Health
923 open questions
Attention Deficit Hyperactivity Disorder
839 open questions
Schizophrenia research and treatment
709 open questions
281 open questions have been extracted from the limitations and future-work passages of 1,693 COVID-19 Clinical Research Studies papers in our library. Each one below links back to the study that raised it, so you can read the original claim in context.

Tools for your next paper

Gaps & Literature SearchFind open questions in any field — 120,000+ open gaps mined from our own library.Pre-CheckIs your paper ready? A Tier 1–5 acceptance probability in seconds.Journal FinderA ranked shortlist of target journals from a 17,500-venue index.Duplicate Publication CheckerCheck prior-publication & salami-slicing risk across 8 sources.Citation GeneratorFreeA DOI or title → APA, MLA, Vancouver, Chicago, BibTeX, RIS. No signup.Graphical Abstract MakerFreeTurn your findings into a colorblind-safe graphical abstract.

Compare the category — Honest roundups of the AI research tools, ours listed alongside the alternatives.

Command palette

Jump anywhere, run any action.